Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Roche

Evaluate

June 05, 2023

Asco 2023 – Enhertu hits with pan approach

Strong data prompt talk of a tumour-agnostic approval, but regulators could prove reluctant in the broad Her2 setting.

Thumbnail
June 05, 2023

Asco 2023 story roundup

Article image
Vantage logo
June 04, 2023

Asco 2023 – Roche sees Morpheus and takes the red pill

The company’s Tigit data are strong enough for a phase 3 trial to be launched, Asco learns.

Article image
Vantage logo
June 03, 2023

Asco 2023 – six months on Gilead/Arcus’s Tigit deflates

Article image
Vantage logo
June 03, 2023

Asco 2023 – a role for immuno-oncology in ovarian cancer at last?

Astra’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.

Article image
Vantage logo
May 31, 2023

Go or no go? Key FDA decisions for Argenx and Regeneron

Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.

Article image
Vantage logo
May 30, 2023

Asco 2023 preview – Tigit lives again

An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.

Article image
Vantage logo
May 30, 2023

Pfizer posts another haemophilia hit

The group is taking marstacimab to the regulators, but Novo’s MAb looks like a bad omen.

Article image
Vantage logo
May 30, 2023

Asco 2023 preview – a microcap winner

One of the most momentous Asco abstracts drops of recent years sends Verastem up 126%.

Article image
Vantage logo
May 25, 2023

Asco 2023 – Regeneron nips at Bristol’s heels in Lag3

Fianlimab continues to look like biopharma’s leading Lag3 asset, with activity in a new melanoma setting to boot.

Article image
Vantage logo
May 25, 2023

Archer misses the target

Annexon’s failure in geographic atrophy could clear the way for its rivals.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up